Interlude Biopharma Co, a late-stage, drug-development company focused on celiac disease, announced on Thursday the company's public launch at the 21st International Celiac Disease Symposium (ICDS 2026) and introduced plans for a prevention-focused Phase 3 trial to evaluate larazotide acetate as a therapy to protect the gut against gluten-induced injury.
Interlude expects to initiate the study in the first quarter of 2027 in the United States.
Larazotide acetate, Interlude's lead drug candidate, is an oral, locally acting peptide designed to regulate intestinal tight junctions, the gatekeepers of the intestinal barrier, by acting as a zonulin inhibitor. Because it operates at an early, upstream step before an immune response is triggered in the intestine, larazotide acetate's mechanism of action extends beyond celiac disease, offering potential therapeutic applications across any chronic inflammatory disease in which zonulin-mediated barrier dysfunction is implicated, Interlude said.
The FDA has granted Fast Track designation to larazotide acetate for the treatment of celiac disease.
Harbour BioMed's partner Spruce Biosciences separates CRHX-101 into Adrenyx Biosciences
US FDA clears Medtronic plc's Hugo robotic-assisted surgery system for general surgery
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Apotex launches generic version of INLYTA in US market
Genentech secures first FDA approval for primary membranous nephropathy treatment
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder